Patient choice in the evolving haemophilia treatment landscape: what it means and why it matters

Charter 1-3, Manchester Central Convention Complex Wednesday, 8 February 2023 11:30-12:45

This symposium, organised and funded by Pfizer, will feature live presentations and interactive Q&A with experts to enable scientific exchange between attendees and speakers. Active audience participation is encouraged.

This symposium is intended for healthcare professionals with an interest and expertise in haemophilia.

Agenda

Co-chairs: Cedric Hermans (Belgium) and Lisa Wilcox (Pfizer Global Medical Affairs)

Time	Session titles	Presenter
11:30	Welcome and introductions	Cedric Hermans (Belgium) and Lisa Wilcox (Pfizer)
11:33	Scientific principles underpinning novel treatment approaches in haemophilia Presentation (10 mins) and Q&A (4 mins)	Mike Laffan Imperial College, London, UK
11:47	Considerations that inform patient choice in haemophilia <i>Presentation (10 mins) and</i> Q&A (4 mins)	Brian O'Mahony Irish Haemophilia Society, Dublin, Ireland
12:01	Understanding health literacy principles Presentation (10 mins) and Q&A (4 mins)	Simon Fletcher Oxford Haemophilia and Thrombosis Centre, Oxford, UK
12:15	Shared decision making and the role of the multidisciplinary team: from theory to practice <i>Presentation (10 mins) and Q&A (4 mins)</i>	Cedric Hermans Saint-Luc University Hospital, Brussels, Belgium
12:29 14 min	 Questions to the panel – active audience participation This section is designed as an interactive discussion between the panel and the audience – moderated by the (co)-chair(s) It will provide an opportunity for the panel members to share expertise and further insights, as well as answer questions from the audience 	All Moderated by Cedric Hermans (Belgium) and Lisa Wilcox (Pfizer)
12:43	Meeting summary and close	Cedric Hermans (Belgium) and Lisa Wilcox (Pfizer)



